FT: AstraZeneca şi Bristol Myers discută o fuziune de 400 miliarde de dolari - Economica.net

AstraZeneca is in talks with Bristol Myers Squibb for a potential merger valued at around $400 billion, which could create a major pharmaceutical company. The deal may face regulatory hurdles and has led to a drop in AstraZeneca's stock. Investors are questioning the strategic rationale behind the merger.